Biospecimen Bone Infection Registry Finds Higher MRSA Rate in North America

An international, biospecimen registry on Staphylococcus aureus in fixation or arthroplasty showed higher rates of MRSA in North American patients and poorer subjective outcomes among those with MRSA vs. methicillin-sensitive S. aureus.

Researchers from the AO trauma Clinical Priority Program (CPP) collected microbiological and immunological data, including bacterial isolates, blood, and sera, from 292 patients with long bone and joint infections.

“Methicillin-resistant S. aureus (MRSA) was detected in 82 patients (28.4%), with the highest proportion found among patients from North American sites (n=39, 48.8%) and the lowest from Central European sites (n=18, 12.2%),” the researchers wrote in the study. “Although patients improved with treatment, less than two-thirds were cured in 1 year. At 12-month follow-up, patient-reported outcome scores were worse for patients with MRSA infections,” they wrote.

 

Click here to read more.